Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 45, Issue 5, 2011, Pages 1015-1021

  Nassar, Taher ^a   Yarovoi, Serge ^a   Fanne, Rami Abu ^b   Waked, Otailah ^b   Allen, Timothy C ^c   Idell, Steven ^c   Cines, Douglas B ^a   Higazi, Abd Al Roof ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Lung; NMDA R; Permeability; Urokinase

Indexed keywords

EVANS BLUE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PHENYLEPHRINE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL PERMEABILITY; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; HUMAN; HUMAN TISSUE; LUNG BLOOD FLOW; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY ARTERIAL RING; PULMONARY ARTERY; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CAPILLARY PERMEABILITY; FIBRIN; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; PHENYLEPHRINE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TISSUE CULTURE TECHNIQUES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

MUS;

EID: 80555125051     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0302OC     Document Type: Article

References (43)

1. Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. Am J Physiol Lung Cell Mol Physiol 2008;295:L967-L975.
2. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003;31:S213-S220. (Pubitemid 36458170)
3. Idell S, James K, Levin E, Schwartz B, Manchanda N, Maunder R, Martin T, McLarty J, Fair D. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989;84:695-705. (Pubitemid 19197006)
4. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman H. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl JMed 1990;322:890-897. (Pubitemid 20108378)
5. Barazzone C, Belin D, Piguet F, Vassalli J, Sappino A. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996;98:2666-2673. (Pubitemid 26427390)
6. Nassar T, Yarovoi S, Abu Fanne R, Akkawi S, Jammal M, Allen T, Idell S, Cines D, Higazi A. Regulation of airways contractility by plasminogen activators through NMDA receptor-1. Am J Respir Cell Mol Biol 2010; (In press)
7. Kwak S, Mitra S, Bdeir K, Strassheim D, Park J, Kim J, Idell S, Cines D, Abraham E. The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with aVβ3 integrins. J Leukoc Biol 2005;78:937-945. (Pubitemid 41384410)
8. Massey P, Tanaka S, Buckler J, Jiang B, McCourtie A, Qian K, Tom C, Stempien-Otero A, Wen S, Luttrell I, et al. Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains. Thromb Haemost 2009;102:983-992.
9. Martin-McNulty B, Zhang L, da Cunha V, Vincelette J, Rutledge J, Vergona R, Sullivan M, Wang Y. Urokinase-type plasminogen activator deficiency (uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice. Transl Res 2007;149:70-75. (Pubitemid 46107906)
10. Kiyan J, Kusch A, Tkachuk S, Krämer J, Haller H, Dietz R, Smith G, Dumler I. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor. Atherosclerosis 2007;195:254-261. (Pubitemid 350087953)
11. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiologic angiogenesis. Proc. Natl. Acad. Sci. USA 1992;89:10686.
12. Odekon L, Sato Y, Rifkin D. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992;150:258-263.
13. Pepper M, Belin D, Montesano R, Orci L, Vassalli J. Transforming growth factor-beta 1 modulated basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990;111:743-755.
14. Van Hinsbergh VWM, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. In: Goldberg ID, Rosen EM, editors. Regulation of angiogenesis. Basel: Birkhauser Verlag; 1997. pp. 391-411.
15. Higazi AA-R, Upson R, Cohen R, McCrae KR, Manuppello J, Bognacki J, Henkin J, Kounnas M, Strickland D, Preissner KT, et al. Interaction of single chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 1996;88:542-551. (Pubitemid 26240386)
16. Nassar T, Haj-Yeha S, Akkawi S, Kuo A, Bdeir K, Mazar A, Cines DB, Higazi A. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem 2002;277:40499-40504. (Pubitemid 35215627)
17. Armstead WM, Cines DB, Bdeir K, Stein SC, Higazi AA. uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res 2008;1231:121-131.
18. Abraham E, Kuhn K, Arcoli J, Strassheim D, Park JS, Shetty S, Idell S. Urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation. J Immunol 2003;I170:5644-5651. (Pubitemid 36617856)
19. Haj-Yejia A, Nassar T, Sachais BS, Kuo A, Bdeir K, Al-Mehdi AB, Mazar A, Cines DB, Higazi AA-R. Urokinase-derived peptides regular vascular smooth muscle cell contraction in vitro and in vivo. FASEB J 2000;14:1411-1422. (Pubitemid 30439750)
20. Armstead WM, Cines BC, Higazi A. Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury. J Neurotrauma 2004;21:1204-1211. (Pubitemid 39280847)
21. Armstead W, Cines D, Higazi A. Plasminogen activators contribute to age dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res 2005;156:139-146. (Pubitemid 41132123)
22. Said S, Berisha H, Pakbaz H. Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. USA 1996;93:4688-4692.
23. Kathleen G, Dickman J, Youssef G, Mathew M, Said S. Ionotropic glutamate receptors in lungs and airway: molecular basis for glutamate toxicity. Am J Respir Cell Mol Biol 2004;30:139-144. (Pubitemid 38147198)
24. Gill S, Mueller R, Peter P, Mcguire F, Olga O, Pulido M. Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicol Pathol 2000;28:277-284. (Pubitemid 30173835)
25. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.
26. Armstead W, Cines D, Higazi A. Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 2005;36:2265-2269. (Pubitemid 41429257)
27. Lopez-Atalaya J, Roussel B, Levrat D, Parcq J, Nicole O, Hommet Y, Benchenane K, Castel H, Leprince J, To Van D, et al. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab 2008;28:1212-1221. (Pubitemid 351733345)
28. Zhang L, Strickland DK, Cines DB, Higazi AA-R. Regulation of single chain urokinase binding, internalization and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Cheml 1997;272:27053-27057. (Pubitemid 27452660)
29. Akkawi S, Nassar T, Tarshis M, Cines BC, Higazi A. LRP and avB3 mediate tPA-activation of smooth muscle cells. Am J Physiol Heart Circ Physiol 2006;291:H1351-H1359.
30. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, Heyman S, Higazi A. The in vitro and in vivo effect of tPA and PAI-1 on blood vessel tone. Blood 2004;103:897-902. (Pubitemid 38129548)
31. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 1994;2:566-574.
32. Pinsky D, Liao H, Lawson C, Yan S, Chen J, Carmeliet P, Loskutoff D, Stern D. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular deposition. J Clin Invest 1998;102:919-928. (Pubitemid 28419237)
33. Bone RC, Francis PB, Pierce AR. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976;61:585-589.
34. Bachofen M, Weibel E. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982;3:35-56. (Pubitemid 12062058)
35. Neuhof H, Seeger W, Wolf HRD. Generation of mediators by limited proteolysis during blood coagulation and fibrinolysis: its pathogenetic role in the adult respiratory distress syndrome (ARDS). Resuscitation 1986;14:23-32. (Pubitemid 16031075)
36. Gyetko M, Chen G-H, McDonald RA, Goodman R, Huffnagle GB, Ilkinson CCW, Fuller JA, Toews GB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans: a murine transgenic model. J Clin Invest 1996;97:1818-1826.
37. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa inefection. J Immunol 2000;165:1513-1519. (Pubitemid 30604586)
38. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-237. (Pubitemid 26021713)
39. Gunther A, Lubke N, Ruppert C, Weissma N, Grimmminger F, Seeger W. Prevention of lung fibrosis in a rabbit model of bleomycin-induced fibrosis upon aerosol application of heparin or urokinase. Chest 2001;120:4-10.
40. Wagers S, Norton R, Rinaldi L, Bates J, Sobel B, Irvin C. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest 2004;114:104-111. (Pubitemid 39071649)
41. Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani T, Sisson R, Simon, Nishimura Y. Inhalation of urokinase-type plasminogen activator (uPA) reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol 2008;114:104-111.
42. Hofstra J, Haitsma J, Juffermans N, Levi M, Schultz M. The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost 2008;34:475-484.
43. Idell S, Koenig K, Fair D, Martin T, McLarty J, Maunder R. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991;261:L240-L248.